生产企业：Medivir AB
Fostroxacitabine bralpamide (fostrox) is an investigational, liver-targeted, orally administered prodrug of troxacitabine developed by Medivir AB for the treatment of advanced hepatocellular carcinoma and other liver cancers. It utilizes first-pass metabolism to selectively deliver the DNA replication inhibitor troxacitabine to liver tumors, minimizing systemic toxicity. In a phase 1b/2a study, fostrox combined with lenvatinib demonstrated promising efficacy and a favorable safety profile as second-line therapy in patients with advanced HCC who had previously received immunotherapy. An ongoing randomized phase 2 trial is further evaluating the combination versus lenvatinib monotherapy.
Fostroxacitabine bralpamide (fostrox) is an investigational, liver-targeted, orally administered prodrug of troxacitabine developed by Medivir AB for the treatment of advanced hepatocellular carcinoma and other liver cancers. It utilizes first-pass metabolism to selectively deliver the DNA replication inhibitor troxacitabine to liver tumors, minimizing systemic toxicity. In a phase 1b/2a study, fostrox combined with lenvatinib demonstrated promising efficacy and a favorable safety profile as second-line therapy in patients with advanced HCC who had previously received immunotherapy. An ongoing randomized phase 2 trial is further evaluating the combination versus lenvatinib monotherapy.
Fostroxacitabine bralpamide (fostrox) is a liver-targeted prodrug that delivers the cell-killing compound troxacitabine selectively to liver tumors while minimizing systemic exposure. It is designed using first-pass metabolism: the prodrug is administered orally and travels inactive to the liver, where local activation and release of troxacitabine takes place. Troxacitabine is an inhibitor of DNA replication; once released in the liver, it induces DNA damage selectively in tumor cells. This liver-directed delivery mechanism aims to maximize anti-tumor efficacy locally while minimizing harmful effects on normal cells and preserving liver function.
Fostroxacitabine bralpamide is being investigated in combination with lenvatinib as a second-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have previously received immunotherapy. It has potential applicability in primary liver cancer and liver metastases from other tumor types.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
